Clinical Trials Logo

Clinical Trial Summary

Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05080868
Study type Observational
Source Central Hospital, Nancy, France
Contact
Status Completed
Phase
Start date March 23, 2021
Completion date August 15, 2021

See also
  Status Clinical Trial Phase
Terminated NCT00744185 - Propranolol in Capillary Hemangiomas Phase 2/Phase 3
Completed NCT00601016 - A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy Phase 2